ucc home | site map | Site Feedback
Study at UCC | Current Students | Research | Staff | Teaching & Learning | Visitors | Alumni | About UCC

Publications

 

 

 

Gleeson BM, Martin K, Ali MT, Kumar AH, Pillai MG, Kumar SP, O'Sullivan JF, Whelan D, Stocca A, Khider W, Barry FP, O'Brien T, Caplice NM. Therapy. Stem Cells. 2015 May 12

Ryan PM, Guinane CM, London LE, Kelleher PR, Fitzgerald GF, Caplice NM, Ross RP, Stanton C. Genome Sequence of the Heteropolysaccharide-Producing Strain Lactobacillus mucosae DPC 6426. Genome Announc. 2015 Jan 15

Huang CL, Leblond AL, Turner EC, Kumar AH, Martin K, Whelan D, O'Sullivan DM, Caplice NM. Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction. Mol Pharm. 2015

 Ryan PM, Ross RP, Fitzgerald GF, Caplice NM, Stanton C. Sugar-coated: Exopolysaccharide producing lactic acid bacteria for food and human health applications. Food Funct. 2015

London LE, Kumar AH, Wall R, Casey PG, O'Sullivan O, Shanahan F, Hill C, Cotter PD, Fitzgerald GF, Ross RP, Caplice NM, Stanton C. Exopolysaccharide-producing probiotic lactobacilli reduce serum cholesterol and modify enteric microbiota in apoe-deficient mice. J Nutr. 2014;144:1956-1962

Whelan D, Caplice NM, Clover AJ. Fibrin as a delivery system in wound healing tissue engineering applications. J Control Release. 2014;196C:1-8

Clover AJ, Kumar AH, Isakson M, Whelan D, Stocca A, Gleeson BM, Caplice NM. 2014. Allogeneic mesenchymal stem cells, but not culture modified monocytes, improve burn wound healing. Burns Sep 15. pii: S0305-4179(14)00278-2

Kumar AH, Martin K, Doyle B, Huang CL, Pillai GK, Ali MT, Skelding KA, Wang S, Gleeson BM, Jahangeer S, Ritman EL, Russell SJ, Caplice NM.. “Stent-based Vascular cell Delivery for Therapeutic Angiogenesis” Biomaterials 2014 Aug 2. pii: S0142-9612(14)00810-2

Turner EC, Huang CL, Govindarajan K, Caplice NM. Identification of a Klf4-dependent Upstream Repressor Region Mediating Transcriptional Regulation of the Myocardin Gene in Human Smooth Muscle Cells. Biochim Biophys Acta Sep 20. pii: S1874-9399(13)00134-X

Martin K, Kumar AH, Klinkert K Caplice NM. Differential Endothelial Coverage, Response to Injury and Neointimal Integration of CX3CR1/Smooth Muscle-like Cells after Carotid or Femoral Arterial Injury. J Vasc Res May 3;50(3):200-209

Martin K, Huang CL, Caplice N,  Regenerative Approaches to Post-Myocardial Infarction Heart Failure Current Pharmaceutical Design  2013 Jun 18. [Epub ahead of print]

Kumar AHS, Martin K, Turner EC, Buneker CK, Dorgham K, Deterre P, Caplice NM  Role of CX3CR1 Receptor in Monocyte/Macrophage Driven Neovascularization. PLoS ONE (2013) 8(2): e57230. doi:10.1371/journal.pone.0057230

O'Sullivan JF, Leblond AL, Hristova I, O’Dea J, Martin K, Kumar AH, Kumar S, Caplice NM. Dynamic Contrast Enhanced CT (DCE-CT) Accurately Measures Myocardial Infarct Size, But Not Microvascular Obstruction (MVO) or Dynamic Changes in Regional Myocardial Blood Flow. J Am Coll Cardiol 2013 Jan 15;61(2):208-10

Hynes B, Kumar AH, O'Sullivan JF, Leblond AL, Weiss S, Schmeckpeper J, Martin K, Caplice NM. Potent EPC conditioned media related anti-apoptotic, cardiotrophic and proangiogenic effects post myocardial infarction are mediated by IGF1. Eur Heart J Dec 15 2011.

Clover AJ, Kumar AH, Caplice NM. Deficiency of CX3CR1 delays burn wound healing and is associated with reduced myeloid cell recruitment and decreased sub-dermal angiogenesis. Burns. 2011 Sep 15.

Martin K, O'Sullivan JF, Caplice NM. New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Curr Opin Cardiol 2011 Sept 13.

O'Sullivan JF, Leblond AL, Kelly G, Kumar AH, Metharom P, Buneker CK, Alizadeh-Vikali N, Hristova I, Hynes BG, O'Connor R, Caplice NM. Potent Long-Term Cardioprotective Effects of Single Low-Dose Insulin-Like Growth Factor-1 Treatment Postmyocardial Infarction. Circulation Cardiovascular Interventions 2011 Jun 29.

Caplice NM, Role of vessel wall and bone marrow syndecan-4 in neointimal hyperplasia: the plot thickens. Arterioscler Thromb Vasc Biol. 2011;31(5):952-3

Metharom P, Martin K, Kumar A, Sawhney N, Cronin M, McCarthy D, Maguire AR, Caplice NM. Pleiotropic role for monocyte C-fms protein in response to vascular injury: Potential therapeutic target. Atherosclerosis. 2011;Feb 2.

Kumar AH, McCauley SD, Hynes BG, O'Dea J, Caplice NM. “Improved protocol for processing stented porcine coronary arteries for immunostaining.” J Mol Histol. 2011 Feb 9.

O'Sullivan JF, Martin K, Caplice NM. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis "a finger in the dam". J Am Coll Cardiol. 2011;57(4):383-9.

Caplice NM, Martin K. Contrast-enhanced ultrasound and the enigma of plaque neovascularization. JACC Cardiovasc Imaging. 2010;3(12):1273-5.

Kumar AH, Caplice NM. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol. 2010;30:1080-1087

Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, O'Sullivan J, Caplice N. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, rhoa, and myocardin. Circ Res. 2009:CIRCRESAHA.109.199984

Schmeckpeper J, Ikeda Y, Kumar AH, Metharom P, Russell SJ, NM C. Lentiviral tracking of vascular differentiation in bone marrow progenitor cells. Differentiation. 2009 Sep-Oct;78(2-3):169-76

Kumar AH, Metharom P, Schmeckpeper J, Weiss S, Martin K, Caplice NM. Bone marrow-derived cx3cr1 progenitors contribute to neointimal smooth muscle cells via fractalkine cx3cr1 interaction. Faseb J. 2009;24:81-92

Metharom P, Kumar AH, Weiss S, Caplice NM. A specific subset of mouse bone marrow cells has smooth muscle cell differentiation capacity-brief report. Arterioscler Thromb Vasc Biol. 2009;30:533-535

Metharom P, Liu C, Wang S, Stalboerger P, Chen G, Doyle B, Ikeda Y, Caplice NM. Myeloid lineage of high proliferative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo. Atherosclerosis. 2008;198:29-38

Doyle B, Sorajja P, Hynes B, Kumar AH, Araoz PA, Stalboerger PG, Miller D, Reed C, Schmeckpeper J, Wang S, Liu C, Terzic A, Kruger D, Riederer S, Caplice NM. Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including tgfbeta1. Stem Cells Dev. 2008;17:941-951

Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol. 2007;49:2073-2080

Caplice NM, Wang S, Tracz M, Croatt AJ, Grande JP, Katusic ZS, Nath KA. Neoangiogenesis and the presence of progenitor cells in the venous limb of an arteriovenous fistula in the rat. Am J Physiol Renal Physiol. 2007;293:F470-475

Metharom P, Caplice NM. Vascular disease: A new progenitor biology. Curr Vasc Pharmacol. 2007;5:61-68

Metharom P, Doyle B, Caplice NM. Clinical trials in stem cell therapy: Pitfalls and lessons for the future. Nat Clin Pract Cardiovasc Med. 2007;4 Suppl 1:S96-99

Doyle B, Metharom P, Caplice NM. Endothelial progenitor cells. Endothelium. 2006;13:403-410

Doyle B, Caplice NM. Targeting angiogenesis versus myogenesis with cardiac cell therapy. Expert Rev Cardiovasc Ther. 2006;4:745-753

Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, Wang XL, Lee HC, Caplice NM, Packer DL. Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation. 2006;113:2485-2494

Caplice NM. The future of cell therapy for acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3 Suppl 1:S129-132

Doyle B, Caplice N. Letter regarding article by rotmans et al, "in vivo cell seeding with anti-cd34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts". Circulation. 2005;112:e359; author reply e359-360

Davies WR, Wang S, Oi K, Bailey KR, Tazelaar HD, Caplice NM, McGregor CG. Cyclosporine decreases vascular progenitor cell numbers after cardiac transplantation and attenuates progenitor cell growth in vitro. J Heart Lung Transplant. 2005;24:1868-1877

Caplice NM, Gersh BJ, Alegria JR. Cell therapy for cardiovascular disease: What cells, what diseases and for whom? Nat Clin Pract Cardiovasc Med. 2005;2:37-43

Deb A, Wang SH, Skelding K, Miller D, Simper D, Caplice N. Bone marrow-derived myofibroblasts are present in adult human heart valves. J Heart Valve Dis. 2005;14:674-678

Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, Caplice NM. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial c-reactive protein on various human endothelial cell types in vitro: Implications of contaminating presence of sodium azide in commercial preparation. Circ Res. 2005;97:135-143

Doyle B, Caplice N. A new source of endothelial progenitor cells--vascular biology redefined? Trends Biotechnol. 2005;23:444-446

Caplice NM, Doyle B. Vascular progenitor cells: Origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem Cells Dev. 2005;14:122-139

Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005;106:1525-1531

Novo G, Caplice N, Tantillo R, Bonura F, Simari R, Novo S. Tfpi antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. Int Angiol. 2005;24:366-371

Caplice NM, Deb A. Myocardial-cell replacement: The science, the clinic and the future. Nat Clin Pract Cardiovasc Med. 2004;1:90-95

Liu C, Nath KA, Katusic ZS, Caplice NM. Smooth muscle progenitor cells in vascular disease. Trends Cardiovasc Med. 2004;14:288-293

Deb A, Skelding KA, Wang S, Reeder M, Simper D, Caplice NM. Integrin profile and in vivo homing of human smooth muscle progenitor cells. Circulation. 2004;110:2673-2677

Deb A, Caplice NM. Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27:258-264

Katusic ZS, Caplice NM, Nath KA. Nitric oxide synthase gene transfer as a tool to study biology of endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:1990-1994

Simper D, Wang S, Deb A, Holmes D, McGregor C, Frantz R, Kushwaha SS, Caplice NM. Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation. 2003;108:143-149

Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, Litzow MR, Edwards WD. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003;100:4754-4759

Deb A, Wang S, Skelding KA, Miller D, Simper D, Caplice NM. Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation. 2003;107:1247-1249

Caplice NM, Gersh BJ. Stem cells to repair the heart: A clinical perspective. Circ Res. 2003;92:6-8

Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation. 2002;106:1199-1204

Panetta CJ, Miyauchi K, Berry D, Simari RD, Holmes DR, Schwartz RS, Caplice NM. A tissue-engineered stent for cell-based vascular gene transfer. Hum Gene Ther. 2002;13:433-441

Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Jr., Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis. Blood. 2001;98:2980-2987

Stalboerger PG, Panetta CJ, Simari RD, Caplice NM. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost. 2001;86:923-928

Singh R, Pan S, Mueske CS, Witt T, Kleppe LS, Peterson TE, Slobodova A, Chang JY, Caplice NM, Simari RD. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res. 2001;89:71-76

Caplice NM. Biologic alternatives to stents and grafts. Curr Cardiol Rep. 2001;3:17-21

Caplice NM. The artificial artery. Curr Interv Cardiol Rep. 2000;2:7-10

Caplice NM, Simari RD, Holmes DR. Molecular biology and gene transfer in atherosclerosis in the stenting era. Int J Cardiovasc Intervent. 1999;2:141-152

Caplice N, Simari R. Gene transfer for coronary restenosis. Curr Interv Cardiol Rep. 1999;1:157-164

Caplice NM, Mueske CS, Kleppe LS, Peterson TE, Broze GJ, Jr., Simari RD. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res. 1998;83:1264-1270

Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation. 1998;98:1051-1057

Caplice NM, Aroney CN, Bett JH, Cameron J, Campbell JH, Hoffmann N, McEniery PT, West MJ. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. J Am Coll Cardiol. 1997;29:1536-1541

Caplice NM, West MJ, Campbell GR, Campbell J. Inhibition of human vascular smooth muscle cell growth by heparin. Lancet. 1994;344:97-98

 

Back to Top